Srpski
+381 64 251 88 20
+381 64 251 88 20

Our licences

Treatment of Cytostatic Agranulocytosis by Means of Transplantation of Fetal Liver Hemopoietic Cells

Smikodub A.I., Radzievskaya L.V., Snigir N.V.

Cell Therapy Clinic of National Medical University and Embryonic Tissues Center EmCell

Cytostatic neutropenia is one of the main factors promoting the development of infectious complications in oncologic patients. The complex of treatment of patients suffering from agranulocytosis caused by a standard chemotherapy was added with transplantation of hemopoietic fetal cell suspensions. For transplantation were used cryopreserved cell suspensions, each of them produced from human liver of one embryo 7 to 12 weeks of gestation. One transplantation was used for each patient; amount of administered cells was 0.5 to 4.0*108/ml, CFU-GM 0.6 to 165*105, CFU-GEMM 2.1 to 9.0*105.

Observed were 25 patients suffering from cytostatic agranulocytosis: 17 from acute leukosis, 2 from leukemization of lymphoma, 1 from blastic crisis of chronic myeloblastic leukosis, 4 from solid tumors, and 1 from acute myelosane aplasia. In 19 patients cytostatic neutropenia was complicated by the development of infections.

On the 1st–3rd day after transplantation, clinical improvement in the form of decrease or normalization of the body temperature and decrease of manifestation of the intoxication syndrome was observed in 14 out of 19 patients having infection symptoms.

An increase in amounts of leukocytes and neutrophils was recorded since the 3rd day; however, a valid increase was revealed since the 11th day. On the 3rd day, the amount of neutrophils was 0.40±0.12*109/l (p>0.05), and on the 11th day, 1.79±0.76*109/l (p<0.05) as against 0.18±0.07*109/l prior to transplantation.

An improvement of indices of erythrocytes and thrombocytes, as well as regression of infection manifestations was also noted.

Therapy appeared to be ineffective in five patients (20%).

Rezultat tretmana fetalnim matičnim ćelijama zavisi od: težine bolesti, starosne dobi pacijenta, doslednosti i privrženosti medikaciji i režimu. Rezultati tretmana, prezentovani na ovom sajtu, su individualni za svaki klinički slučaj.